Art. 107b Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 13×
1.

Marketing authorisation holders shall submit to the Agency periodic safety update reports containing:

(a)

summaries of data relevant to the benefits and risks of the medicinal product, including results of all studies with a consideration of their potential impact on the marketing authorisation;

(b)

a scientific evaluation of the risk-benefit balance of the medicinal product;

(c)

all data relating to the volume of sales of the medicinal product and any data in possession of the marketing authorisation holder relating to the volume of prescriptions, including an estimate of the population exposed to the medicinal product.

The evaluation referred to in point (b) shall be based on all available data, including data from clinical trials in unauthorised indications and populations.

The periodic safety update reports shall be submitted electronically.

2.

The Agency shall make available the reports referred to in paragraph 1 to the national competent authorities, the members of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use and the coordination group by means of the repository referred to in Article 25a of Regulation (EC) No 726/2004.

3.

By way of derogation from paragraph 1 of this Article, the holders of marketing authorisations for medicinal products referred to in Article 10(1), or Article 10a, and the holders of registrations for medicinal products referred to in Articles 14 or 16a, shall submit periodic safety update reports for such medicinal products in the following cases:

(a)

where such obligation has been laid down as a condition in the marketing authorisation in accordance with Article 21a or Article 22; or

(b)

when requested by a competent authority on the basis of concerns relating to pharmacovigilance data or due to the lack of periodic safety update reports relating to an active substance after the marketing authorisation has been granted. The assessment reports of the requested periodic safety update reports shall be communicated to the Pharmacovigilance Risk Assessment Committee, which shall consider whether there is a need for a single assessment report for all marketing authorisations for medicinal products containing the same active substance and inform the coordination group or the Committee for Medicinal Products for Human Use accordingly, in order to apply the procedures laid down in Article 107c(4) and Article 107e.

The 10 that are cited most themselves, of 13.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…28Law

    … actualisés de sécurité, conformément à l’article 28, paragraphe 2, du présent règlement, en liaison avec l’article 107 ter de la directive 2001/83/CE. 16. L’obligation de procéder à des études après mise sur le marché, …

  • Directive (EU) 2010/842Law

    … De nationale kompetente myndigheder sikrer, at den i artikel 107b, stk.1, i direktiv 2001/83/EF som ændret ved dette direktiv, fastsatte forpligtelse for indehaveren af markedsføringstilladelsen til at forelægge elektroniske periodiske, …

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…1Law

    … Povinnosti držitelů rozhodnutí o registraci stanovené v článku 107b směrnice 2001/83/ES a postupy podle článků 107b a 107c uvedené směrnice se vztahují na předkládání pravidelně aktualizovaných zpráv o bezpečnosti, …

  • Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law

    … 28 odst. 2 nařízení (ES) č. 726/2004 ve spojení s článkem 107b směrnice 2001/83/ES; 16) povinnost provést studie po uvedení na trh, včetně poregistrační studie bezpečnosti a poregistrační studie účinnosti a předložit …

  • Regulation (EU) 2019/5Law

    … 28 odst. 2 tohoto nařízení ve spojení s článkem 107b směrnice 2001/83/ES; 16) povinnost provést studie po uvedení na trh, včetně poregistrační studie bezpečnosti a poregistrační studie účinnosti a předložit je k …

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … 28 odst. 2 nařízení (ES) č. 726/2004 ve spojení s článkem 107b směrnice 2001/83/ES; 16) povinnost provést studie po uvedení na trh, včetně poregistrační studie bezpečnosti a poregistrační studie účinnosti a předložit …

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … periodic safety update reports, in accordance with Article 28(2) of Regulation (EC) No 726/2004 read together with Article 107b of Directive 2001/83/EC; the obligation to conduct post-marketing studies, including post-authorisation safety …

  • Arzneimittelgesetz2bLaw

    … aktualisierter Bericht über die Unbedenklichkeit von Arzneimitteln (PSUR)“ ist ein Bericht mit den in Art. 107b der Richtlinie 2001/83/EG genannten Aufzeichnungen. (10) „Unbedenklichkeitsstudie nach Zulassung“ ist jede klinische …

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    Il convient de rappeler que, en vertu de l’article 107 ter de la directive 2001/83, « [l]es titulaires d’une [AMM] soumettent à l’[EMA] des rapports périodiques actualisés de sécurité contenant : a) des résumés des …

    2 Mar 2022 · 62020TJ0556

  • Judgment of the Court (Third Chamber) of 25 November 2021. Delfarma Sp. z o.o. v Prezes Urzędu Rejestracji Produktów Leczniczych, Wyrobów MeDecision

    Thus, under Article 104 of that directive, the MA holder must implement a pharmacovigilance system. In that respect, it is responsible, inter alia, for updating the risk management system and monitoring pharmacovigilance data in order to …

    25 Nov 2021 · 62020CJ0488